Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically- matched diabetic controls

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 585-597

  Zhao, Yang ^a   Ye, Wenyu ^a   Le, Trong K ^a   Boye, Kristina S ^a   Holcombe, John H ^a   Swindle, Ralph ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetic neuropathy; ER; Healthcare charges; Hospitalization; Illness burden; Utilization

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AMPUTATION; ARTICLE; BIPOLAR DEPRESSION; BREAST CANCER; CHOLELITHIASIS; COMORBIDITY; CONTROL GROUP; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETIC NEUROPATHY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; GENERAL ASPECTS OF DISEASE; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART DISEASE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; KNEE OSTEOARTHRITIS; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PHARYNGITIS; PHYSICIAN; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN INFECTION; SPRAIN; THORAX PAIN; UNITED STATES;

EID: 67649382166     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802706289     Document Type: Article

References (20)

1. Centers for Disease Control. National diabetes fact sheet. United States, 2005. Available at http://www.ndep.nih.gov/diabetes/pubs/2005-National- Diabetes-Fact-Sheet.pdf [Last accessed June 17, 2008]
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
3. Booya F, Bandarian F, Larijani B, et al. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurology 2005;5:24 (Pubitemid 41829848)
4. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality of life issues. Mayo Clinic Proceedings 2006;81:3-11
5. Hall G, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156-162
6. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-962 (Pubitemid 40434506)
7. Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9-15 (Pubitemid 40973398)
8. Greene DA. Presentation, diagnosis, and classification of diabetic neuropathy in older adults. Ann Long-Term Care 2000;8:51-58
9. Vinik EJ, Hayes C, Oglesby A, et al. Identification of factors in the nerve fiber specific quality of life (QOL-DN) inventory that reflect QOL and health status. Program and abstracts from the 64th Scientific Sessions of the American Diabetes Association, June 4-8, 2004; Orlando, Florida. Abstract 1212-P
10. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life. Neurology 2007;68:1178-1182
11. Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia 2003;43:957-973 (Pubitemid 30655714)
12. Le TK, Able SL, Lage MJ. Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression. Cost Eff Resour Alloc 2006;4:18 (Pubitemid 44650763)
13. Zhao Y, Ye W, Boye, KS, et al. Prevalence of other diabetes-associated complications and co-morbidities and its impact on healthcare charges among patients with diabetic neuropathy. J Diabetes Complicat. Available online at http://dx.doi.org/10.1016/j.jdiacomp.2008.09.001 (Accessed January 2009)
14. Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care 2005;43:34-43 (Pubitemid 40137612)
15. Pope GC, Liu CF, Ellis RP, et al. Principal inpatient diagnostic cost group models for Medicare risk adjustment. Final report to the Health Care Financing Administration under Contract No 50095-51048 Waltham, MA: Health Economics Research, February, 1999
16. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004;25:119-141 (Pubitemid 39201560)
17. Zhao Y, Kuo T, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 2008;8:108 (Pubitemid 351840944)
18. Kuo T, Zhao Y, Weir S, et al. Implications of comorbidity on costs for patients with Alzheimer disease. Med Care 2008;46:839-846
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853
20. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986 (Pubitemid 23307905)